30
Participants
Start Date
July 4, 2016
Primary Completion Date
July 25, 2016
Study Completion Date
October 10, 2016
SCMC-lys powder 1.35 g
"Powder for oral solution in sachets each containing 1.35 g of S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys).~One sachet of the powder of the test formulation: (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was dissolved in 100 mL of hot (not boiling) still mineral water. Additional 100 mL of still mineral water at room temperature were added and mixed. The solution was swallowed and the glass was rinsed with 40 mL of still mineral water that was also drunk by the subjects. The final administered volume was 240 mL. All subjects were in fasting conditions from the evening before (at least 10 h, overnight).The final administered volume was 240 mL for both the test and reference treatments."
Fluifort® syrup
"Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g SCMC-lys)~Fifteen (15) mL of syrup (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) poured in a glass were drunk by the subjects. Afterward, the glass was rinsed twice with a volume of 100 mL and 125 mL of still mineral water and the rinses were drunk immediately by the subjects. The final administered volume was 240 mL for both the test and reference treatments."
CROSS Research S.A., Phase I Unit, Arzo
Collaborators (1)
Cross Research S.A.
INDUSTRY
Dompé Farmaceutici S.p.A
INDUSTRY